The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 18, 2023
Filed:
Jul. 17, 2020
Applicant:
Incelldx, Inc., San Carlos, CA (US);
Inventors:
Edgar B. Francisco, San Carlos, CA (US);
Hallison Rodrigues, San Carlos, CA (US);
Amruta Pise, San Carlos, CA (US);
Bruce K. Patterson, Menlo Park, CA (US);
Assignee:
IncellDx, Inc., San Carlos, CA (US);
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61P 31/14 (2006.01); C07K 14/52 (2006.01); C07K 14/47 (2006.01); A61K 31/46 (2006.01); C07D 451/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2866 (2013.01); A61K 31/46 (2013.01); A61P 31/14 (2018.01); C07D 451/00 (2013.01); C07K 14/4722 (2013.01); C07K 14/523 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C12N 2770/20011 (2013.01);
Abstract
Methods of treating a subject suffering from COVID-19 are provided. Aspects of the methods including administering to the subject an effective amount of an inhibitor of CCR5/CCL5 interaction, such as a CCR5 antagonist. Also provided are methods of assessing severity of a disease involving hypercytokinemia, such as COVID-19, by determining the level of CCL5/RANTES in a subject, as well as compositions for use in such methods.